1. World Health Organization (2024) Diabetes. https://www.who.int/news-room/fact-sheets/detail/diabetes. Accessed 13 May 2024.
2. Rakesh KS, Richa G, Jayashree VS, Sandeep KG, Brij M, Prakash K, Ravindra KS, Vinayak MS, Ashutosh M, Sreenivasa ML, Vivek VA, Abhijit RS, Pravin NS, Sandip KG, Shital RK, Mandodari NR, Piyush MP, Lalit KL, Suyog CM, Sadhna JJ (2023) Fixed-dose combination of dapagliflozin + sitagliptin + metformin in patients with type 2 diabetes poorly controlled with metformin: phase 3, randomized comparison with dual combinations. Adv Ther 40(7):3227–3246. https://doi.org/10.1007/s12325-023-02523-z
3. National Centre for Biotechnology Information (2024) PubChem Compound Summary for CID 9887712, Dapagliflozin. https://pubchem.ncbi.nlm.nih.gov/compound/Dapagliflozin Accessed 27 May 2024
4. National Centre for Biotechnology Information (2024) PubChem Compound Summary for CID 4369359, Sitagliptin. https://pubchem.ncbi.nlm.nih.gov/compound/Sitagliptin Accessed 27 May 2024
5. National Centre for Biotechnology Information (2024) PubChem Compound Summary for CID 4091, Metformin. https://pubchem.ncbi.nlm.nih.gov/compound/Metformin Accessed 27 May 2024